DR. ERKUT BORAZANCI
Affectionately Referred To As “Dr. B” By His Patients
According to MediFind, it identifies Dr. Erkut Borazanci among its “Top 10 Elite Experts” that lead the fight against pancreatic cancer. That distinguished group also includes Dr. Douglas B. Evans who is also a member the Seena Magawitz Foundation’s Medical Advisory Council.
Dr. Erkut Borazanci is a medical oncologist and clinical investigator at HonorHealth Research Institute. He is also the Director of its Early Detection Program. He also holds adjunct appointments as clinical associate professor at the
Translational Genomics Research Institute (TGen) and clinical assistant professor at the University of Arizona.
MediFind deems Dr. Borazanci one of the global leaders in the field of pancreatic cancer. These global leaders have published many articles about pancreatic cancer in medical journals, speak at medical conferences and are lead investigators in multiple pancreatic cancer clinical trials.
Dr. Borazanci is among the super heroes leading the way on the discovery of cutting edge of innovative pancreatic cancer treatments that are saving lives and extending the life of pancreatic cancer patients.
Dr. Erkut Borazanci is a leading pancreatic cancer researcher at the HonorHealth Reseaarch Institute in Scottsdale, Arizona where he is the principle clinical investigator for several pancreatic cancer clinical trials and leads its Early
He is affectionately referred to as “Dr. B” by his many patients who are participants in his clinical trials and directs his patients’ treatment at the Virginia G. Piper Cancer Center at the HonorHealth Research Institute. He works closely
with Dr. Daniel Von Hoff at the Translational Genomic Research Institute (TGen) in Phoenix to advance more promising treatments for pancreatic cancer.
Dr. Boraznci has been an author on 26 peer reviewed articles and been principal investigator of 42 clinical trials. In particular, he has been an author on 18 peer reviewed articles and has been principal investigator in 24 clinical
trials regarding Pancreatic Cancer. Additionally, he has been an author of 50 abstracts presented at various research meetings including AACR, ASCO, and ESM.